Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Effect of Dapagliflozin on Clinical Outcomes in Patients with Chronic Kidney Disease, With and Without Cardiovascular Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Challenges in catheter ablation of deep myocardial substrate for ventricular tachycardia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Atrial fibrillation is a marker of increased mortality risk in non-ischemic heart failure - results from the DANISH Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. A novel approach for obtaining 12-lead electrocardiograms in horses

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Deep sedation as temporary bridge to definitive treatment of ventricular arrhythmia storm

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Milton Packer
  • Stefan D Anker
  • Javed Butler
  • Gerasimos Filippatos
  • João Pedro Ferreira
  • Stuart J Pocock
  • Peter Carson
  • Inder Anand
  • Wolfram Doehner
  • Markus Haass
  • Michel Komajda
  • Alan Miller
  • Steen Pehrson
  • John R Teerlink
  • Martina Brueckmann
  • Waheed Jamal
  • Cordula Zeller
  • Sven Schnaidt
  • Faiez Zannad
Vis graf over relationer

BACKGROUND: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, with or without diabetes, but additional data are needed about the effect of the drug on inpatient and outpatient events that reflect worsening heart failure.

METHODS: We randomly assigned 3730 patients with class II to IV heart failure with an ejection fraction of ≤40% to double-blind treatment with placebo or empagliflozin (10 mg once daily), in addition to recommended treatments for heart failure, for a median of 16 months. We prospectively collected information on inpatient and outpatient events reflecting worsening heart failure and prespecified their analysis in individual and composite end points.

RESULTS: Empagliflozin reduced the combined risk of death, hospitalization for heart failure or an emergent/urgent heart failure visit requiring intravenous treatment (415 versus 519 patients; empagliflozin versus placebo, respectively; hazard ratio [HR], 0.76; 95% CI, 0.67-0.87; P<0.0001). This benefit reached statistical significance at 12 days after randomization. Empagliflozin reduced the total number of heart failure hospitalizations that required intensive care (HR, 0.67; 95% CI, 0.50-0.90; P=0.008) and that required a vasopressor or positive inotropic drug or mechanical or surgical intervention (HR, 0.64; 95% CI, 0.47-0.87; P=0.005). As compared with placebo, fewer patients in the empagliflozin group reported intensification of diuretics (297 versus 414 [HR, 0.67; 95% CI, 0.56-0.78; P<0.0001]). Additionally, patients assigned to empagliflozin were 20% to 40% more likely to experience an improvement in New York Heart Association functional class and were 20% to 40% less likely to experience worsening of New York Heart Association functional class, with statistically significant effects that were apparent 28 days after randomization and maintained during long-term follow-up. The risk of any inpatient or outpatient worsening heart failure event in the placebo group was high (48.1 per 100 patient-years of follow-up), and it was reduced by empagliflozin (HR, 0.70; 95% CI, 0.63-0.78; P<0.0001).

CONCLUSIONS: In patients with heart failure and a reduced ejection fraction, empagliflozin reduced the risk and total number of inpatient and outpatient worsening heart failure events, with benefits seen early after initiation of treatment and sustained for the duration of double-blind therapy. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03057977.

OriginalsprogEngelsk
TidsskriftCirculation
Vol/bind143
Udgave nummer4
Sider (fra-til)326-336
Antal sider11
ISSN0009-7322
DOI
StatusUdgivet - 26 jan. 2021

ID: 62372975